Athero-Screen

Despite effective lipid-lowering therapies, patients remain at risk of cardiovascular disease. By 2030, cardiovascular disease (CVD) is expected to affect about 41% of the Western population. This increase will significantly raise healthcare costs, with U.S. expenditures on CVD projected to triple between 2010 and 2030. Many CVD drugs fail in clinical trials due to a […]

GlycoMASH

GlycoMASH aims to develop a blood test that can detect liver damage before it becomes life-threatening. Liver fibrosis, often observed in fatty liver disease, progresses silently and affects millions globally. People with type 2 diabetes (T2D) are especially vulnerable, of which 65% have fatty liver disease and around 15% progress to advanced liver fibrosis. Current […]

Detecting Parkinson

Parkinson’s disease (PD) affects about 10 million people worldwide, and cases are expected to double by 2050. Yet there is still no cure. Because we lack objective tools to monitor disease biology, it is difficult to assess new treatments, and diagnosis often arrives after irreversible brain damage has occurred. Our answer to this problem is […]

ChemoPredict

All of us have a relative or know someone who has been diagnosed with cancer. The disease brings significant uncertainty, including difficult treatment decisions. Chemotherapy is often a key option and can be highly effective, but for ovarian cancer patients with recurrent disease, the likelihood of benefit can drop below 30%. With ChemoPredict, VitroScan provides […]

Gutsense

Our project, GutSense, aims to help people who struggle with digestive issues due to food intolerances, like those triggered by lactose or certain sugars. Currently, testing for these intolerances is complicated, expensive, and not always accurate. Many people suffer from bloating, cramps, and discomfort, which greatly affects their daily lives and well-being. Our solution is […]

Alzheimer’s proteomics for disease diagnosis and patient stratification

Alzheimer’s Disease (AD) is a worldwide problem that does not yet have a clear solution. Although new treatments are starting to emerge, they do not work for every patient. The reason is likely individual difference in the specific, molecular, causes of AD. In our project, we will explore an innovative method to classify AD patients […]

Leiden Analytics

Technologies to help us understand the biology underlying drug response are in high demand, as many patients do not respond to treatments. Identifying potential responders is particularly important in modern cancer care, where therapies are potentially very effective yet extremely expensive. There is need of more in-depth understanding of which rare cell populations, (e.g. inside […]

TRITON-Disposable PoP tests for early detection of lung cancer

With around 1.8 million new cases per year, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer deaths globally. We are developing disposable, inexpensive optical biosensors for label-free detection of cancer biomarkers. Our main value proposition is to improve early lung cancer diagnosis with rapid, accessible, and cost-effective diagnostic […]

Huntington biomarker detection in tears

Huntington’s disease (HD) is a progressive, ultimately lethal, genetic disorder caused by a mutation in the gene coding for the protein mutant Huntingtin (mHTT). Despite numerous genetic intervention trials, there are currently no treatments that can slow down HD’s progression. To develop new treatments it is important to monitor disease progression and the effectivity of […]

Giant Extracellular Vesicles (GEVs)

Imagine if we could tell patients if they are cancer-free, how advanced it is, or which drugs work best for their treatment, all by analyzing a blood or urine sample. Our technology does precisely that. It functionally identifies unique molecules in tiny bubble-like containers called extracellular vesicles that come from diseased cells. These molecules act […]